Sethuraman Natarajan — SEC insider filings
SEC reporting owner CIK 1873394. 23 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 23 filings on record, filed 2021-11-01 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 21 legs across 10 filings — 110,025 shares, $1,904,498 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: sale of 25,907 shares @ $15.39 ($398,810) in Entrada Therapeutics, Inc., filed 2026-05-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | President, Research & Develop. | 23 | — | 21 legs · 110,025 sh · $1,904,498 | 32 |
Insider filings — Sethuraman Natarajan
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 2,079 @ $7.14 | EDGAR |
| 2026-05-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 25,907 @ $15.39 | EDGAR |
| 2026-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 55,800 @ $0 · Tax withholding (F): 3,898 @ $11.66 · Tax withholding (F): 7,577 @ $11.76 · Grant/award (A): 83,200 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 1,760 @ $5.43 | EDGAR |
| 2025-03-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 60,800 @ $0 · Tax withholding (F): 6,138 @ $11.68 · Grant/award (A): 90,800 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 100 @ $20 · Sale (S): 4,088 @ $20.26 · Sale (S): 11,703 @ $20.15 | EDGAR |
| 2024-11-13 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,409 @ $20.01 · Sale (S): 2,700 @ $20.04 | EDGAR |
| 2024-11-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 749 @ $18.02 · Sale (S): 5,171 @ $18.18 · Sale (S): 9,554 @ $18.71 · Sale (S): 2,745 @ $19.32 | EDGAR |
| 2024-10-18 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 600 @ $18 | EDGAR |
| 2024-09-10 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 600 @ $15.24 · Sale (S): 2,642 @ $15.09 | EDGAR |
| 2024-09-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 469 @ $15.76 · Tax withholding (F): 151 @ $16.93 · Tax withholding (F): 14 @ $17.70 · Tax withholding (F): 955 @ $15.42 · Tax withholding (F): 167 @ $15.13 | EDGAR |
| 2024-07-16 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 600 @ $18 · Sale (S): 638 @ $18 | EDGAR |
| 2024-05-20 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,000 @ $15 · Sale (S): 8,305 @ $15.14 · Sale (S): 9,675 @ $15.19 | EDGAR |
| 2024-03-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 44,100 @ $0 · Tax withholding (F): 347 @ $12.42 · Tax withholding (F): 414 @ $13.37 · Tax withholding (F): 1,505 @ $12.28 · Grant/award (A): 66,800 (derivative) @ $0 | EDGAR |
| 2023-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 14,200 @ $0 · Tax withholding (F): 449 @ $14.46 · Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,026 @ $18.00 · Sale (S): 14,852 @ $18.04 | EDGAR |
| 2023-04-19 | 4/A | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 14,200 @ $0 · Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-04-19 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,961 @ $18.00 | EDGAR |
| 2023-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 28,400 @ $0 · Tax withholding (F): 1,058 @ $11.60 · Grant/award (A): 43,000 (derivative) @ $0 | EDGAR |
| 2022-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 5,794 @ $0 | EDGAR |
| 2022-07-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 34,763 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 11,588 @ $0 · Grant/award (A): 69,525 (derivative) @ $0 | EDGAR |
| 2021-11-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 243,639 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-27 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1873394 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs